Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Multiple Sclerosis and Hyperprolactinemia: A Case–Control Study Publisher Pubmed



Etemadifar M1 ; Najafi MA3 ; Najafi MR1 ; Alavi A2 ; Nasr Z2 ; Farokhi M4, 5, 8 ; Rezaei A6, 7
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Neurology, Alzahra Hospital, Isfahan University of Medical Sciences, Isfahan, Iran
  2. 2. Isfahan University of Medical Sciences, Isfahan, Iran
  3. 3. Isfahan Neurosciences Research Centre (INRC), Affiliated to Isfahan University of Medical Sciences, Isfahan, Iran
  4. 4. Department of Neurology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
  5. 5. Multiple Sclerosis and Neuroimmunology Research Center, Isfahan, Iran
  6. 6. Department of Molecular Biology, Cell Biology, and Biochemistry, Brown University, Providence, 02912, RI, United States
  7. 7. Department of Neuroscience, Brown University, Providence, 02912, RI, United States
  8. 8. Immunology Department, Isfahan University of Medical Sciences, Isfahan, Iran

Source: Acta Neurologica Belgica Published:2015


Abstract

Multiple sclerosis (MS) is an autoimmune disease of central nervous system which is characterized with demyelination. Prolactin, synthesized in the anterior pituitary cells, has a role in maturation of immune cells, suggesting its possible implication in autoreactivity. The aim of the current study is to investigate the role of hyperprolactinemia in MS. Twenty-two MS patients with hyperprolactinemia diagnosed with pituitary adenoma and 66 MS patients without hyperprolactinemia were enrolled in our case–control study. They were matched with regard to age, gender, and MS subtypes. Patients with other concomitant autoimmune diseases and pregnancy were excluded. Statistical analyses were carried out using SPSS (SPSS statistic package, version 21.0.0) statistical software. The Pearson Chi-square test and the t test were used to determine whether there were any significant differences. The level of significance was set at p < 0.05. Greater value of relapse rate among hyperprolactinemic MS patients in comparison to non-hyperprolactinemic MS patients was statistically significant (p < 0.001). Statistically significant difference between the two groups in terms of EDSS was observed (case group vs. control: 1.3 vs. 1.9; p = 0.007). The correlation between MS duration and duration of hyperprolactinemia was significant in the case group (p < 0.05, R = 0.752). No statistically significant difference was found between two groups regarding duration of MS. This study suggested a protective role of prolactin in demyelinating procedure of MS. © 2014, Belgian Neurological Society.
Other Related Docs
19. Prevalence of Familial Multiple Sclerosis in Isfahan, Iran, Journal of Isfahan Medical School (2011)
34. Clinical and Epidemiological Aspects of Multiple Sclerosis in Children, Iranian Journal of Child Neurology (2017)
38. The Association of Multiple Sclerosis With Thyroid Disease: A Meta-Analysis, Multiple Sclerosis and Related Disorders (2023)
48. A Novel Approach to Discriminate Subgroups in Multiple Sclerosis, Iranian Journal of Allergy, Asthma and Immunology (2016)